Barbara Ziffels1, Francesca Pretto2, Dario Neri1. 1. Department of Chemistry & Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, (ETH Zürich), Vladimir-Prelog-Weg 1-5/10, CH-8093 Zürich, Switzerland. 2. Philochem AG, Libernstrasse 3, CH-8112 Otelfingen, Switzerland.
Abstract
AIM: The combination of tumor-targeting IL2- and TNF-based antibody-cytokine fusions has exhibited encouraging results in mouse and men. Here, we studied their combination to assess efficacy and mechanism of action in four different immunocompetent mouse models of cancer. METHODS: Mice receiving a single intratumoral injection of F8-IL2, F8-TNF or the combination were investigated for tumor-infiltrating leukocytes and rechallenged when cured. RESULTS: In three models, a proportion of treated animals could be cured, most probably by infiltrating NK and CD8+ T cells. Most of the cured mice did not acquire protective immunity when rechallenged with the same tumor cell line. CONCLUSION: Immunocompetent mouse tumor models may not be adequate enough to predict the search for more efficacious therapy regimens.
AIM: The combination of tumor-targeting IL2- and TNF-based antibody-cytokine fusions has exhibited encouraging results in mouse and men. Here, we studied their combination to assess efficacy and mechanism of action in four different immunocompetent mouse models of cancer. METHODS: Mice receiving a single intratumoral injection of F8-IL2, F8-TNF or the combination were investigated for tumor-infiltrating leukocytes and rechallenged when cured. RESULTS: In three models, a proportion of treated animals could be cured, most probably by infiltrating NK and CD8+ T cells. Most of the cured mice did not acquire protective immunity when rechallenged with the same tumor cell line. CONCLUSION: Immunocompetent mouse tumor models may not be adequate enough to predict the search for more efficacious therapy regimens.
Entities:
Keywords:
EDA domain of fibronectin; IL2; TNF; immunocytokines; intratumoral injection
Authors: Jocelyn Lippey; Rhiannon Bousounis; Cori Behrenbruch; Bartholomew McKay; John Spillane; Michael A Henderson; David Speakman; David E Gyorki Journal: J Surg Oncol Date: 2016-05-30 Impact factor: 3.454
Authors: Benjamin Weide; Thomas K Eigentler; Annette Pflugfelder; Henning Zelba; Alexander Martens; Graham Pawelec; Leonardo Giovannoni; Pier Adelchi Ruffini; Giuliano Elia; Dario Neri; Ralf Gutzmer; Jürgen C Becker; Claus Garbe Journal: Cancer Immunol Res Date: 2014-04-04 Impact factor: 11.151
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Barbara Ziffels; Marco Stringhini; Philipp Probst; Tim Fugmann; Theo Sturm; Dario Neri Journal: Mol Cancer Ther Date: 2019-06-18 Impact factor: 6.261
Authors: Joseph R Palmeri; Emi A Lutz; Noor Momin; Noor Jailkhani; Howard Mak; Anthony Tabet; Magnolia M Chinn; Byong H Kang; Virginia Spanoudaki; Richard O Hynes; K Dane Wittrup Journal: Nat Commun Date: 2022-01-10 Impact factor: 14.919